Vertex Pharmaceuticals (VRTX) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) in the last few weeks:

• 8/5/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/5/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $560.00 to $565.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Vertex Pharmaceuticals had its price target raised by Barclays PLC from $615.00 to $617.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by TD Cowen from $525.00 to $550.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals was given a new $500.00 price target by Stifel Nicolaus.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $436.00 to $442.00. They now have a “hold” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by Cantor Fitzgerald from $590.00 to $595.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – Vertex Pharmaceuticals was upgraded by Sanford C. Bernstein to “strong-buy”.
• 7/17/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 7/13/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group AG from $545.00 to $585.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $542.00 to $560.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $543.00 to $570.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 6/28/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/20/2026 – Vertex Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 4,062 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $450.00, for a total transaction of $1,827,900.00. Following the completion of the sale, the chief marketing officer owned 16,953 shares in the company, valued at $7,628,850. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares in the company, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,464 shares of company stock valued at $4,959,397 over the last quarter. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.